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Abstract
Background: A number of synthetic pantothenate derivatives, such as pantothenamides, are known to inhibit the
growth of the human malaria parasite Plasmodium falciparum, by interfering with the parasite Coenzyme A (CoA)
biosynthetic pathway. The clinical use of pantothenamides is limited by their sensitivity to breakdown by
ubiquitous human pantetheinases of the vanin family.
Methods: A number of pantothenate derivatives (pantothenones) with potent and specific inhibitory activity
against mammalian vanins were tested in a proliferation assay of asexual P. falciparum blood stages alone, and in
combination with pantothenamides.
Results: The vanin inhibitors were found to protect pantothenamides against breakdown by plasma vanins, thereby
preserving the in vitro anti-malarial activity. Moreover, some of the vanin inhibitors showed in vitro anti-malarial activity
in the low micromolar range. The most potent antimalarial in this series of compounds (RR8), was found to compete
with pantothenate in a combination proliferation assay. No correlation, however, was found between anti-vanin and
anti-malarial activity, nor was pantetheinase activity detected in P. falciparum extracts.
Conclusions: Growth inhibition is most likely due to competition with pantothenate, rather than pantetheinase
inhibition. As vanin inhibitors of the pantothenone class are stable in biological fluids and are non-toxic to
mammalian cells, they may represent novel pantothenate-based anti-malarials, either on their own or in
combination with pantothenamides.
Keywords: Malaria, Anti-malarial, Plasmodium falciparum, Pantothenate, Pantothenic acid, Pantothenamide,
Pantothenone, Coenzyme A
Background
Each year over half a million people die of malaria, with
Plasmodium falciparum being the primary cause of fatal
malaria cases [1]. As the eradication of malaria is threat-
ened by occurrence of clinical resistance to artemisinin
derivatives, new drugs for malaria are sorely needed and
so the search for new lead compounds continues [1].
Based on the observation, that addition of calcium
pantothenate to Plasmodium lophurae cultures increased
parasite viability, a selection of analogues of pantothenate
(pantothenic acid, vitamin B5), were tested for antiplas-
modial activity as early as the 1940s [2]. These compounds
included pantoyltaurine, substituted pantoyltaurylamides,
sulphonamides, and pantothenones, according to the no-
menclature used in a review on this subject by Spry et al.
[3]. These and similar compounds were tested in different
in vitro and in vivo malaria models from the 1960s and
1970s [4,5]. In 1976, Trager and Jensen published an art-
icle describing the continuous culture of P. falciparum [6],
allowing Divo et al. to discover that pantothenate is
indeed the only water soluble vitamin that needs to be ex-
ogenously available for P. falciparum survival [7]. Mean-
while, Clifton et al. prepared a series of analogues with the
general structure N1-(substituted) pantothenamide, and
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found them to have antibacterial activity due to being an-
timetabolites of pantothenate [8].
Recent studies showed that some of the pantothena-
mides were also active against P. falciparum in vitro, pro-
vided that plasma pantetheinase activity was reduced [9].
This was discovered due to the observation that ‘aging’
P. falciparum growth media increased the anti-malarial ac-
tivity of some pantothenamides [9]. Later, this same effect
was achieved with heat inactivation of the parasite growth
medium by de Villiers et al. [10]. The mechanism of break-
down of pantothenamides by pantetheinases of the vanin
family was elucidated in detail by Jansen et al. who discov-
ered that combining pantothenamides with small molecule
vanin inhibitors, protected pantothenamides against break-
down, thereby dramatically increasing their antibacterial
activity against both Staphylococcus aureus and Escherichia
coli [11-14]. It has also been shown by de Villiers et al. that
small modifications of the pantothenamide core structure
could protect the molecule against pantetheinase-mediated
degradation, albeit at a cost of a 100-fold decrease in anti-
malarial potency [10].
Compounds, such as the pantothenamides in E. coli or
the fungal product CJ-15,801 in S. aureus may hijack
Coenzyme A (CoA) biosynthesis, being phosphorylated
in the first step of the biosynthesis by pantothenate kin-
ase (PanK) and eventually blocking CoA production or
interfering with fatty acid synthesis downstream along
the pathway [15-17]. Almost a decade ago, the fungal
product CJ-15,801, was also discovered to have modest
anti-malarial activity against asexual intra-erythrocytic
stages of P. falciparum in vitro, and was demonstrated to
inhibit parasite growth by a mechanism related to CoA
biosynthesis or utilization [18].
In this study a selection of novel pantetheine analogues
of the pantothenone class were investigated for potential
use as anti-malarial chemotherapy. The investigated com-
pounds are shown to be conceptually promising either as
a monotherapy or in a combination of drugs.
Methods
Compounds
Pantothenol was purchased from Sigma-Aldrich. De-
tailed synthesis procedures of CJ-15,801 and CXP14.1-
060 are provided as Additional file 1. The methodologies
for synthesis of CXP14.1-034, RR2, RR6, RR7, RR8 and
SN12,601 have been previously published in Jansen et al.
[13]. N5-Pan and N7-Pan were synthesized as described
in the supplemental material of Jansen et al. [14]. N9-
Pan was synthesized as N5-Pan and N7-Pan, but instead
of using a pentylamine or heptylamine, a nonylamine
was used for the synthesis of N9-Pan. The synthesis of
SN14,621 and SN14,622 was performed as described in
Winterbottom et al. [19]. The synthesis of phenethyl-
Pan was performed as described by Spry et al. [9].
Chemical structures for all of the compounds in this
study are presented in Figure 1.
Plasmodium falciparum culture
The asexual stages of the NF54 strain P. falciparum were
cultured as previously described [6], utilizing a shaker
system with automated media change twice a day, parasites
were kept in continuous culture within adapted Erlen-
meyer flasks [20]. Erythrocytes were refreshed every two or
three days to adjust haematocrit to 5% and parasitaemia to
0.5%. Human erythrocytes (blood type A) were obtained
from healthy blood donors, with no history of malaria.
Culture media consisted of RPMI 1640 with HEPES
[5.94 g/l, hypoxanthine [0.05 g/l], 10% (v/v) pooled human
serum (blood type A) obtained similarly to erythrocytes,
and 0,2% (w/v) sodium bicarbonate. Temperature was set
to 37°C and a low oxygen gas mixture was constantly
flushed over the culture maintaining a stable atmosphere
of 3% O2, 4% CO2, and 93% N2.
Vanin activity assay
Vanin/pantetheinase activity assay with aminomethyl-
coumarine (AMC) substrate and fluorescence readout
was performed as described previously in Jansen et al.
[13,21]. Human serum was used as a source of vanin
enzymatic activity in assays to determine the anti-vanin
activity of study compounds CJ-15,801, SN 12,601, SN
14,621, SN 14,622, CXP14.1-034, CXP14.1-060, RR2, RR6,
RR7, and RR8. To determine whether P. falciparum para-
sites harbour vanin activity, assays were performed on para-
site extracts. To this end, 5 to 9 x 108 non-synchronous
asexual NF54 strain P. falciparum parasites were pelleted
by centrifugation at 4000 rpm for 10 minutes. Pellets were
re-suspended in 5 ml of 0.06% saponin in phosphate buff-
ered saline (PBS) and incubated on ice for 5 minutes to re-
move erythrocytes. After this they were washed with PBS
twice, with centrifugation in between as when pelleting
cultures. Pellets from four different cultures were
individually resuspended in a total volume of 300 μl of
PBS and lysed by sonication (6 x 3 seconds). Vanin ac-
tivity was determined by combining 29 μl of lysate with
1 μl of AMC substrate (final concentration of 333 μM)
and incubation at room temperature. At 0, 1 and
19 hours, 3 μl of the reaction was diluted with 997 μl of
PBS and fluorescence was measured in a 200 μl aliquot.
Assay negative controls consisted of 29 μl of PBS and
1 μl of AMC substrate. Positive control consisted of
19 μl of PBS, 10 μl of human serum, and 1 μl of AMC
substrate.
Plasmodium falciparum asexual blood stages assay with
SYBR Green read-out
A non-synchronous asexual NF54 strain P. falciparum
culture was adjusted to a parasitaemia of 0.5-1% and a
Pett et al. Malaria Journal  (2015) 14:169 Page 2 of 8
haematocrit of 1-5%. The compound dilution curves were
prepared in dimethylsulphoxide (DMSO) from 100 mM
to 10 μM at half/log step dilutions. The established anti-
malarial dihydroartemisinin (DHA) was used as a positive
control and diluted in DMSO from 1 mM to 100 nM at
half/log step dilutions. The DMSO dilutions were 500-fold
diluted in growth medium to yield a final DMSO concen-
tration of 0.2% (v/v), and final compound concentrations
from 200 μM to 20 nM (2 μM to 200 pM for DHA).
Higher concentrations for the experimental compounds
would not have been possible to achieve due to limita-
tions in final DMSO concentration (0.1% v/v). Fifty μl of
each compound dilution was combined with 50 μl of
parasite culture in a black, clear-bottomed or entirely
black 96-well plate. The outermost wells were filled with
sterile water to prevent evaporation. DHA at a concen-
tration of 1 μM and 0.1% DMSO (negative control) were
used to determine the assay window. The 96-well plates
were incubated for 72 hours in a candle jar at 37°C.
Read-out was done using the DNA-marker SYBR Green
as described previously [22,23]. All assays were con-
ducted at least in triplicate.
When combining two compounds in the same well the
conditions were otherwise similar to the single compound
assays, however the final DMSO concentration was 0.2%,
which was also adjusted for the positive and negative
controls and was not found to cause differences in results
obtained with single compounds in assay containing
0.1% DMSO. The pantothenamide phenethyl-Pan was
combined with a 10−7 to 10−5 M concentration curve of
CXP14.1-060; the other pantothenamides were combined
only with a 5 μM concentration of the same vanin inhibi-
tor. The pantothenone vanin inhibitor RR8 was addition-
ally combined with 20 μM, 6.3 μM, 2.0 μM, and 0.6 μM of
pantothenate to explore potential competition for the
same molecular target in P. falciparum. All assays were
conducted at least in triplicate.
Statistical analyses
Statistical analyses were performed using GraphPad
Prism 5. This includes producing inhibition curves, nor-
malizing them to percentage of inhibition, calculation
of IC50 values, correlation coefficients (Spearman non-
parametric correlation), and Schild analyses [24]. The
IC50 is the concentration of the compound in question
at which the compound reaches 50% inhibition relative
to the DHA control curve, and is calculated using the
interpolate function in GraphPad Prism 5.
Figure 1 Chemical structures of all the compounds tested in this study.
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Results
Anti-malarial activity of pantothenamides
Using P. falciparum cultured in 10% human serum, the
low level of anti-malarial activity of the pantothenamides
N5-Pan, N7-Pan and phenethyl-Pan was confirmed, as
shown in Figure 2A. None of these pantothenamides
showed an IC50 below 50 μM. In addition, N9-Pan was
tested. N9-Pan is a pantothenamide that has previously
been shown to have modest antibacterial activity but
had not been investigated for its anti-malarial activity
[8]. N9-Pan was found to be clearly more potent than
the other pantothenamides, with an IC50 of about
15 μM, in the presence of serum (Figure 2A). To investi-
gate the effect of vanin inhibition on the potency of the
pantothenamides N5-Pan, N7-Pan and N9-Pan, these
were combined with 5 μM of the newly synthesized vanin
inhibitor CXP14.1-060, that has nanomolar potency against
human vanins, yet no anti-malarial activity up to the high-
est concentration tested (100 μM) (Table 1). The potency
of N5-Pan and N7-Pan increased upon vanin inhibition,
but the effect was not as great as with phenethyl-Pan
(Figure 2B). Remarkably, the potency of N9-Pan was not
increased by the addition of the vanin inhibitor (Figure 2B).
The potency of DHA did not change upon addition of
5 μM of the vanin inhibitor CXP14.1-060 (Figure 2C).
Phenethyl-Pan was selected to further investigate
the protective effect of the synthetic vanin inhibitor
CXP14.1-060 on its anti-malarial activity. Phenethyl-Pan
was previously shown to have an IC50 of 20 nM in ‘aged’
medium and is the most potent anti-malarial pantothena-
mide known so far [9]. A dose range of this compound
was tested in the presence of varying concentrations of
CXP14.1-060 (Figure 3). The potency of phenethyl-Pan
visibly improved upon addition of increasing concentra-
tions of CXP14.1-060, reaching an IC50 of 23 nM (95% CI:
16.5-31.9 nM) upon addition of 10 μM of CXP14.1-060
(Figure 3). In the presence of 10 μM of vanin inhibitor
CXP14.1-060, phenethyl-Pan showed a full inhibition of
parasite growth, comparable to the efficacy of DHA,
which was used as a reference compound and has an IC50
in the low nanomolar range. This experiment shows that
small molecule inhibition of pantothenamide hydrolysis
will allow the same level of protection found in heat-
inactivated medium as shown by the comparable IC50
values [10].
Figure 2 Anti-malarial activity of pantothenamides. Four
pantothenamides, phenethyl-Pan, but also N5-Pan, N7-Pan and
N9-Pan in asexual blood-stages proliferation assay with SYBR Green
read-out, without and in combination with 5 μM of vanin inhibitor
CXP14.1-060. A) N5-Pan, N7-Pan, N9-Pan and phenethyl-Pan without
vanin inhibitor CXP14.1-060. B) N5-Pan, N7-Pan, N9-Pan and
phenethyl-Pan in combination with vanin inhibitor CXP14.1-060.
C) DHA with and without 5 μM of vanin inhibitor CXP14.1.-060.
Table 1 IC50 values for individual compounds
Anti-malarial activity Anti-vanin activity*
Compound IC50 (μM) 95% C.I. (μM) IC50 (μM)
Pantothenol >100 NA NT
CJ-15,801 >100 NA 213.60
SN 12,601 6.1 4.5-8.7 17.61
SN 14,621 33.6 7.3-NA 33.70
SN 14,622 7.4 3.5-20.7 31.89
CXP14.1-034 24.1 11.3-NA 1.69
CXP14.1-060 >100 NA 0.039
RR2 2.6 2.1-3.3 2.85
RR6 14.5 5.3-NA 0.04
RR7 7.7 5.1-12.6 0.11
RR8 2.2 1.6-3.1 0.27
N5-Pan 45.1 34.8-60.2 NT
N7-Pan 79.0 34.0-NA NT
N9-Pan 14.6 11.0-20.1 NT
Phenethyl-Pan 98.2 NA NT
*Anti-vanin activity tested in human serum.
NA: Not Applicable.
NT: Not Tested.
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Anti-malarial activity of pantothenones
15 pantothenate derivatives were synthesized and assayed
for anti-malarial activity in the in the presence of 10% hu-
man serum. The structures of these compounds are pre-
sented in Figure 1, and their observed individual biological
effects are presented in Table 1. Some of the newly synthe-
sized vanin inhibitors were structurally similar to panto-
thenate derivatives described in the 1940s, which were
shown to have anti-malarial activity in avian malaria
models [2]. Some of these reference compounds were re-
synthesized, including the pantothenone SN12,601 and the
sulphonamides SN 14,621 and SN 14,622. In this study, they
were found to have moderate activity, and the effect of their
dilution curves on P. falciparum growth are shown in
Figure 4. In addition, pantothenol and CJ-15,801, two natural
compounds with known weak activity against P. falciparum,
were also tested [18,25]. CJ-15,801 was found to be a poor
inhibitor of P. falciparum growth (Table 1 and Figure 4) and
pantothenol showed no anti-malarial activity up to the high-
est concentration tested (100 μM) (Table 1). Out of the
newly synthesized pantothenones, the vanin inhibitor RR8
was the most potent of these compounds, having an IC50
value of 2.2 μM (95% CI: 1.6-3.1 µM) (Table 1 and Figure 4).
Mechanism of anti-malarial activity of pantothenones
It was considered, that the pantetheinase inhibiting ac-
tivity of the new compounds may contribute to anti-
malarial activity. Therefore, the IC50 values of in vitro
inhibition of asexual blood stages of P. falciparum were
plotted against the IC50 values of anti-vanin activity in
human serum (Figure 5). There was no correlation be-
tween these activities, suggesting that pantetheinase
inhibition is not the mode of action of the small mol-
ecule inhibitors in P. falciparum asexual blood stages. In
line with this finding, an assay using the AMC substrate
to detect pantetheinase activity, did not detect hydrolytic
activity in extracts of purified asexual stages of P. falcip-
arum, even after a 19 h incubation period, suggesting
that the parasite lacks such enzyme activity (Figure 6).
This notion was corroborated by a BLAST search that
did not reveal sequences in the P. falciparum genome
database with homology to mammalian vanin genes. In
order to investigate an alternate mode of action, compe-
tition experiments with pantothenate were performed.
To this end, a P. falciparum asexual blood stage growth
assay was performed with eight concentrations of RR8
combined with eight concentrations of pantothenate. An
increase in the IC50 of RR8 was found to occur at addition
of increasing concentrations of pantothenate (Figure 7A).
Upon performing a Schild analysis on the results of the
concentrations, 20 μM, 6.3 μM, 2.0 μM, and 0.6 μM of
pantothenate in combination with a dilution curve of RR8,
the slope of the line in the Schild Plot was 1.087 ± 0.089,
indicating that RR8 and pantothenate are competing for
the same target in P. falciparum (Figure 7B).
Discussion
This study underscores the potential of pantothenate de-
rivatives for anti-malarial therapy, and demonstrates that
the most potent serum-labile anti-malarial pantothena-
mide (phenethyl-Pan) can be effectively protected against
hydrolysis by serum pantetheinases using the novel vanin
inhibitor CXP14.1-060. From a mechanistic point of
view, this study indicates that the pantothenone RR8
Figure 3 Anti-malarial activity of phenetyl-Pan in the presence of varying concentrations of vanin inhibitor CXP14.1-060. Combination of
anti-malarial pantothenamide phenethyl-Pan [9] with novel vanin inhibitor CXP14.1-060. Filled upright triangles represent phenethyl-Pan, with
CXP14.1-060 added at a different concentration for every curve as indicated in figure. At a concentration of 10 μM of CXP14.1-060 phenetyl-Pan
has an IC50 of 23 nM (95% CI: 16.5-31.9 nM).
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exerts its anti-malarial effect through competition with
pantothenate.
In the 1940s, a number of chemical variations on panto-
thenate were synthesized and tested for anti-malarial activ-
ity [2]. These included pantothenones and sulphonamides,
which were found to be active against avian malaria. This
study shows that these compounds are also active against
the human parasite P. falciparum.
Although the new vanin inhibitor CXP14.1-060 effect-
ively protected phenethyl-Pan, such a combination of
drugs would be undesirable from a drug development per-
spective. Clearly, the potency and/or stability of pantothen-
ate derivatives needs to be improved before they can enter
a drug development programme as therapeutic agents for
human malaria infection. Nevertheless, the recent discov-
ery of phenethyl-Pan with an IC50 of 20 nM is encouraging
[9]. Although this compound is unstable in plasma, it illus-
trates that it is realistic and feasible to aim for pantothenate
derivatives active in the low nanomolar range. The study
by de Villiers et al. showed that structural modifications of
pantothenamides can be introduced to confer resistance
to plasma-mediated breakdown [10]. These novel com-
pounds, although less potent than the original pantothena-
mides, are a starting point for further lead optimization
studies [10]. Optimization of the potency would be import-
ant to maximize the risk-benefit of a novel drug, as side ef-
fects may be mediated by low-affinity, off-target effects. In
addition, increasing the potency may lead to a lower effect-
ive dose in humans, and hence impact the cost of treat-
ment. Availability of affordable medicines is an important
driver for success in malaria control, and the goal for de-
velopment of novel drug therapies is to achieve effective
treatment with a total cost of US$1 [26]. In that respect,
the molecules described here provide attractive candidates
as their chemistry is simple, which ensures a low cost of
goods in a manufacturing process.
Many of the marketed anti-malarials and compounds in
the clinical development portfolio originate from whole
Figure 4 Anti-malarial activity of pantothenones and reference compounds. Inhibition curves for all compounds with IC50 values below 100 μM,
and CJ-15,801, against asexual blood stages of P. falciparum in a proliferation assay with a SYBR Green read-out.
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cell phenotypic screening efforts and exert their actions by
inhibiting multiple targets or pathways of the parasite. Al-
though such a polypharmacological profile may be im-
portant to their efficacy, it is an undesirable feature in a
rational medicinal chemistry approach. The exact target of
the anti-malarial pantothenate derivatives has not been
identified unequivocally but is it likely that they exert their
effects by affecting targets dependent on pantothenate. In
theory, the observed effects could still be mediated by ef-
fects on red blood cell biology (e.g., red blood cell panto-
thenate kinases (PANK)) rather than directly on the
parasite. However, the recent discovery of a parasite-
specific pantothenate transporter [27] leaves very little
doubt that the parasite itself is the target of interfering
with pantothenate dependent pathways. Future drug de-
velopment efforts would benefit from information on the
molecular targets of pantothenamides, which would in-
clude both biosynthetic pathways (CoA synthesis, lipid
synthesis, energy metabolism) and pantothenate transport
systems. Structural information, which is available for
mammalian and bacterial PANK, could guide medicinal
chemistry strategies to achieve specific inhibition of the
parasite enzyme and reduce side effects on the host.
Conclusions
Pantothenamides with anti-malarial activity can be pro-
tected from breakdown by ubiquitous pantetheinases of
the vanin family with small molecule pantothenone vanin
inhibitors. Some of these pantothenones exhibit anti-
malarial activity in their own right. Compound series such
as the one tested in this publication should be studied fur-
ther for use as lead compounds for anti-malarial treatment.
Additional file
Additional file 1: Supplemental Materials and Methods. The
supplemental materials and methods explain how the compounds
CJ-15,801 and CXP14.1-060 were synthesized.
Figure 5 Lack of correlation between anti-malarial activity and
anti-vanin activity. The IC50 for inhibition of vanin activity in human
serum was plotted against the anti-malarial IC50 in asexual blood stages
proliferation assay of P. falciparum with SYBR Green read-out. No signifi-
cant correlation was observed. (Spearman rho=0.06079 (p=0.8651)).
Figure 7 Pantothenate competes with RR8. Competition assay
between RR8 and pantothenate (PA), results of Schild analysis. A)
Shifting IC50: Combined data points from three experiments. RR8
with 20.0 μM PA, RR8 with 6.3 μM PA, RR8 with 2.0 μM PA, RR8 with
0.6 μM PA and RR8 alone. B) Schild plot: Combined data points from
three experiments. A slope of 1 is indicative of a competitive
antagonistic relationship between RR8 and PA.
Figure 6 Lack of vanin activity in P. falciparum lysates. Vanin activity
assays were performed using a fluorescent aminomethylcoumarine
(AMC) substrate on lysates of P. falciparum cultures (on the right in
white), and as a positive control human serum (on the left in black).
The figure shows mean relative fluorescence units and standard
deviations from measurements of four independent P. falciparum
cultures. Values were corrected for background fluorescence signals
measured in negative control (PBS) samples.
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